Suppr超能文献

胸肿瘤再放疗时的主动脉剂量限制。

Aortic dose constraints when reirradiating thoracic tumors.

机构信息

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

出版信息

Radiother Oncol. 2013 Mar;106(3):327-32. doi: 10.1016/j.radonc.2013.02.002. Epub 2013 Feb 28.

Abstract

BACKGROUND AND PURPOSE

Improved radiation delivery and planning has allowed, in some instances, for the retreatment of thoracic tumors. We investigated the dose limits of the aorta wherein grade 5 aortic toxicity was observed after reirradiation of lung tumors.

MATERIAL AND METHODS

In a retrospective analysis, 35 patients were identified, between 1993 and 2008, who received two rounds of external beam irradiation that included the aorta in the radiation fields of both the initial and retreatment plans. We determined the maximum cumulative dose to 1 cm(3) of the aorta (the composite dose) for each patient, normalized these doses to 1.8 Gy/fraction, and corrected them for long-term tissue recovery between treatments (NIDR).

RESULTS

The median time interval between treatments was 30 months (range, 1-185 months). The median follow-up of patients alive at analysis was 42 months (range, 14-70 months). Two of the 35 patients (6%) were identified as having grade 5 aortic toxicities. There was a 25% rate of grade 5 aortic toxicity for patients receiving composite doses ≥120.0 Gy (vs. 0% for patients receiving <120.0 Gy) (P=0.047).

CONCLUSIONS

Grade 5 aortic toxicities were observed with composite doses ≥120.0 Gy (NIDR ≥90.0 Gy) to 1cm(3) of the aorta.

摘要

背景与目的

放射治疗技术的改进和计划的完善,使得对胸部肿瘤进行再次放射治疗成为可能。我们研究了主动脉的剂量限制,即在肺肿瘤再放疗后观察到 5 级主动脉毒性的情况下。

材料与方法

在一项回顾性分析中,我们确定了 1993 年至 2008 年间的 35 名患者,这些患者在初始和再治疗计划的放射野中都接受了两次外部束放射治疗,包括主动脉。我们确定了每个患者的主动脉 1cm3(复合剂量)的最大累积剂量,将这些剂量归一化为 1.8Gy/分次,并对两次治疗之间的长期组织恢复进行校正(NIDR)。

结果

两次治疗之间的中位时间间隔为 30 个月(范围为 1-185 个月)。在分析时仍存活的患者中位随访时间为 42 个月(范围为 14-70 个月)。35 名患者中有 2 名(6%)被确定为 5 级主动脉毒性。复合剂量≥120.0Gy(NIDR≥90.0Gy)的患者中,5 级主动脉毒性的发生率为 25%(而复合剂量<120.0Gy 的患者发生率为 0%)(P=0.047)。

结论

当主动脉 1cm3 处的复合剂量(NIDR≥90.0Gy)达到 120.0Gy 时,观察到 5 级主动脉毒性。

相似文献

1
Aortic dose constraints when reirradiating thoracic tumors.
Radiother Oncol. 2013 Mar;106(3):327-32. doi: 10.1016/j.radonc.2013.02.002. Epub 2013 Feb 28.
2
Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):808-15. doi: 10.1016/j.ijrobp.2015.12.007. Epub 2015 Dec 17.
6
Reirradiation of thoracic cancers with intensity modulated proton therapy.
Pract Radiat Oncol. 2018 Jan-Feb;8(1):58-65. doi: 10.1016/j.prro.2017.07.002. Epub 2017 Jul 8.
8
Reirradiation for locally recurrent lung cancer previously treated with radiation therapy.
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):390-6. doi: 10.1016/s0360-3016(01)02644-x.
9
Proton therapy for reirradiation of progressive or recurrent chordoma.
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1107-14. doi: 10.1016/j.ijrobp.2013.09.038.
10
Intensity-modulated stereotactic radiotherapy of paraspinal tumors: a preliminary report.
Neurosurgery. 2004 Apr;54(4):823-30; discussion 830-1. doi: 10.1227/01.neu.0000114263.01917.1e.

引用本文的文献

1
Re-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Transl Lung Cancer Res. 2025 May 30;14(5):1650-1659. doi: 10.21037/tlcr-2025-89. Epub 2025 May 27.
3
Comparative analysis of dose calculation algorithms for CyberKnife-based stereotactic radiotherapy in lung cancer.
Front Oncol. 2023 Oct 2;13:1215976. doi: 10.3389/fonc.2023.1215976. eCollection 2023.
4
Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era.
Front Oncol. 2023 Jan 17;12:1074675. doi: 10.3389/fonc.2022.1074675. eCollection 2022.
7
The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study.
Front Oncol. 2022 Oct 14;12:921473. doi: 10.3389/fonc.2022.921473. eCollection 2022.
8
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.
Cancers (Basel). 2022 Jan 23;14(3):573. doi: 10.3390/cancers14030573.

本文引用的文献

2
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review.
Radiother Oncol. 2012 Nov;105(2):145-9. doi: 10.1016/j.radonc.2012.09.008. Epub 2012 Oct 12.
3
Local heart irradiation of ApoE(-/-) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis.
Radiother Oncol. 2012 Dec;105(3):358-64. doi: 10.1016/j.radonc.2012.08.002. Epub 2012 Sep 5.
4
Stereotactic body radiation therapy in the treatment of multiple primary lung cancers.
Radiother Oncol. 2012 Jul;104(1):19-22. doi: 10.1016/j.radonc.2011.12.005. Epub 2012 Jan 14.
5
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy.
Radiother Oncol. 2011 Nov;101(2):260-6. doi: 10.1016/j.radonc.2011.09.012. Epub 2011 Nov 5.
6
Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.
J Appl Clin Med Phys. 2011 Feb 8;12(2):3368. doi: 10.1120/jacmp.v12i2.3368.
7
Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review.
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):969-77. doi: 10.1016/j.ijrobp.2011.01.069. Epub 2011 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验